Neurophysiological Markers of Elevated Inflammation and Cognitive Impairment in People with HIV
Why It Matters
Identifying MEG‑based biomarkers links HIV‑related inflammation to early cognitive decline, enabling timely therapeutic strategies and improving patient outcomes.
Key Takeaways
- •MEG provides absolute, high‑temporal resolution neural activity measurements.
- •Elevated resting beta power predicts poorer cognitive performance in aging.
- •HIV‑related inflammation correlates with altered brain oscillations detectable by MEG.
- •Normative lifespan MEG data reveal frequency shifts from low to high bands.
- •Limited MEG HIV studies highlight need for biomarker development.
Summary
Dr. Tony Wilson presented his laboratory’s work on neurophysiological markers linking inflammation to cognitive impairment in people living with HIV. Leveraging a multimodal imaging platform—MRI, PET, and especially magnetoencephalography (MEG)—his team investigates how viral‑driven immune activation reshapes brain dynamics across the lifespan.
Wilson emphasized MEG’s unique strengths: non‑invasive, silent acquisition, millimeter spatial precision, millisecond temporal resolution, and, crucially, an absolute measure of local neuronal electrical activity. By applying beam‑forming and time‑frequency decomposition, his group isolates canonical bands (theta, alpha, beta, gamma) and distinguishes spontaneous resting‑state power from task‑evoked oscillations. Their data show that older adults exhibit roughly double the beta‑band response during motor tasks, driven by heightened baseline beta power, which correlates with slower behavioral performance.
A landmark PNAS study from his lab mapped spontaneous activity in 430 participants aged 6‑84, revealing systematic age‑related shifts: lower‑frequency power declines while higher‑frequency power rises. This normative atlas provides a reference for detecting deviations in HIV‑positive cohorts, where inflammation appears to amplify beta and gamma activity, mirroring patterns seen in accelerated aging. Notably, only about 35 MEG studies have examined neuroHIV, underscoring a substantial research gap.
The implications are clear: MEG could serve as a sensitive, quantitative biomarker for early neurocognitive decline in HIV, guiding interventions before overt dementia manifests. Establishing robust normative baselines and expanding MEG investigations will be pivotal for translating these neurophysiological signatures into clinical practice.
Comments
Want to join the conversation?
Loading comments...